Yoon-Koo Kang

24PUBLICATIONS
75CO-AUTHORS
ChemotherapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersOther Asian languages (excl. South-East Asian)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Dec 01, 2025
Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma.

Keun-Wook Lee, Li-Yuan Bai, Minkyu Jung

|May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.

Michael C Heinrich, Jean-Yves Blay, Hans Gelderblom

|Aug 20, 2024
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.

Narikazu Boku, Takeshi Omori, Kohei Shitara

|Jul 12, 2024
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.

Yoon-Koo Kang, Hyung-Don Kim, Jeong Hwan Yook

|Jun 11, 2024
Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis.

Yoon-Koo Kang, Shukui Qin, Keun-Wook Lee

Pageof 4